SAN FRANCISCO, March 23, 2017 /PRNewswire/ -- Veracyte,
Inc. (NASDAQ: VCYT), a genomic diagnostics company focused on
reducing unnecessary surgeries and healthcare costs by resolving
diagnostic uncertainty, today announced that multiple presentations
demonstrating the clinical utility of the Afirma Gene Expression
Classifier (GEC) in thyroid cancer diagnosis will be given by
external researchers at ENDO 2017, the annual conference of The
Endocrine Society, being held April
1-4 in Orlando, Florida, at
the Orange County Convention
Center.
"The evidence for the Afirma Gene Expression Classifier
continues to mount, reinforcing its role as a new standard of care
in thyroid cancer diagnosis," said Bonnie
Anderson, Veracyte's chief executive officer and chairman of
the board. "We are also committed to deploying our world-class
scientific approach, which utilizes advanced genomic science and
machine learning, to further enhance the Afirma GEC, enabling even
more patients to avoid unnecessary thyroid surgery just to get a
diagnosis."
The following abstracts will be presented during ENDO 2017:
Title:
|
Comparison of Local
Histopathology and a Central Pathology Panel in Diagnostic Thyroid
Nodule Surgery from a Multicenter, Blinded Study (poster
#205)
|
Presenter:
|
Michael Shanik, M.D.,
Endocrine Associates of Long Island
|
Date/Time:
|
Saturday, April 1,
1-3 p.m. EDT
|
Location:
|
OCCC-West Hall B
(EXPO Hall)
|
|
|
Title:
|
Noninvasive
Follicular Thyroid Neoplasms with Papillary-Like Nuclear Features
and Indeterminate Cytology Are Afirma GEC Suspicious Which
Facilitates Treatment (poster #146)
|
Presenter:
|
Peter M. Sadow, M.D.,
Ph.D., Harvard Medical School
|
Date/Time:
|
Sunday, April 2, 1-3
p.m. EDT
|
Location:
|
OCCC-West Hall B
(EXPO Hall)
|
|
|
Title:
|
Repeat Biopsy with
Afirma GEC for Indeterminate Thyroid Nodule: An Institutional
Experience (oral presentation #OR38-4)
|
Presenter:
|
Padmaja Akkireddy,
M.D., University of Nebraska
|
Date/Time:
|
Monday, April 3,
12-12:15 p.m. EDT
|
Location:
|
OCCC-Valencia
D
|
Veracyte will also preview an enhanced version of its Afirma
Gene Expression Classifier (GEC) in a Product Theater event to
be held Sunday, April 2, 11:30 a.m. – 12:30 p.m.
EDT (ENDOExpo Theater-Booth #544), which will feature
presentations by Giulia C. Kennedy,
Ph.D., the company's chief scientific officer, Richard T. Kloos, M.D., senior medical director
– endocrinology, and leading external researchers. The
next-generation Afirma GEC will incorporate more refined genomic
information – comprised of gene expression and variant and fusion
data – on a single RNA-sequencing platform to further increase the
number of patients who can potentially avoid unnecessary thyroid
surgery. The company plans to begin making the test available to
physicians later this year.
About the Afirma GEC
The Afirma GEC is used to
identify patients with benign thyroid nodules among those with
indeterminate cytopathology results in order to preserve the
thyroid. Each year in the United
States, more than 525,000 fine needle aspiration biopsies
are performed to assess patients with potentially cancerous thyroid
nodules. Up to 30 percent of the results are indeterminate (not
clearly benign or malignant) and physicians have traditionally
recommended thyroid surgery for a more definitive diagnosis.
Following surgery, however, 70 to 80 percent of patients' nodules
are diagnosed as benign, meaning the surgery was unnecessary. Such
surgery is invasive, costly and often leads to the need for
lifelong daily thyroid hormone replacement drugs.
About Veracyte
Veracyte (NASDAQ: VCYT) is a
leading genomic diagnostics company that is fundamentally improving
patient care by resolving diagnostic uncertainty with evidence that
is trustworthy and actionable. The company's products uniquely
combine genomic technology, clinical science and machine learning
to provide answers that give physicians and patients a clear path
forward without risky, costly surgery that is often unnecessary.
Since its founding in 2008, Veracyte has commercialized three
genomic tests, which are transforming the diagnosis of thyroid
cancer, lung cancer and idiopathic pulmonary fibrosis and
collectively target a $2 billion
market opportunity. Veracyte is based in South San Francisco, California. For more
information, please visit www.veracyte.com and follow the company
on Twitter (@veracyte).
Cautionary Note Regarding Forward-Looking
Statements
This press release contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements can be identified by words such as:
"anticipate," "intend," "plan," "expect," "believe," "should,"
"may," "will" and similar references to future periods. Examples of
forward-looking statements include, among others, our ability to
successfully scale the company and our belief that we are well
positioned for profitable growth. Forward-looking statements are
neither historical facts nor assurances of future performance.
Instead, they are based only on our current beliefs, expectations
and assumptions regarding the future of our business, future plans
and strategies, anticipated events and trends, the economy and
other future conditions. Forward-looking statements involve risks
and uncertainties, which could cause actual results to differ
materially, and reported results should not be considered as an
indication of future performance. These risks and uncertainties
include, but are not limited to: the applicability of clinical
results to actual outcomes; laws and regulations applicable to our
business, including potential regulation by the Food and Drug
Administration or other regulatory bodies; the size of
the market opportunity for our products; our ability to
successfully achieve adoption of and reimbursement for our
products; the amount by which use of our products are able to
reduce invasive procedures and misdiagnosis, and reduce healthcare
costs; the occurrence and outcomes of clinical studies; the timing
and publication of clinical study results; and other risks set
forth in the company's filings with the Securities and
Exchange Commission, including the risks set forth in the company's
Annual Report on Form 10-K for the year ended December 31,
2016. These forward-looking statements speak only as of the date
hereof and Veracyte specifically disclaims any obligation
to update these forward-looking statements.
Veracyte, Afirma, Percepta, Envisia, the Veracyte logo, and the
Afirma logo are trademarks of Veracyte, Inc.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/veracyte-announces-that-multiple-studies-supporting-clinical-utility-of-its-afirma-gene-expression-classifier-to-be-presented-at-endo-2017-300428224.html
SOURCE Veracyte